RXRX - Recursion Pharmaceuticals Stock Is Sliding Wednesday: What's Going On? | Benzinga
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Wednesday after the company reported mixed fourth-quarter financial results.
What Happened: Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The clinical stage biotech company reported a quarterly loss of 42 cents per share, which beat estimates for a loss of 44 cents per share, according to Benzinga Pro.
Recursion said multiple clinical programs from its first generation platform are on track to read out Phase 2 data in the second half of 2024 and first half of 2025.
The company’s in-licensed program (Target Epsilon) that ...